August 06, 2025 a 08:39 pm
CAH: Analysts Ratings - Cardinal Health, Inc.
Cardinal Health, Inc., operating across multiple continents, is witnessing a critical phase with some positive but reserved sentiments from analysts. While the company powers through its diverse healthcare services segments, the latest ratings indicate a strong belief in its sustained growth, with a majority leaning towards a hold or moderate buy stance.
Historical Stock Grades
The following table provides the latest analyst recommendations on the Cardinal Health stock as of August 1, 2025. The data indicates a slight positive sentiment with a dominant inclination towards holding or buying the stock.
| Recommendation Type | Count | Score Bar |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 10 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Examining the progression of analyst ratings over the past months reveals significant trends indicating shifts between buying, holding, and selling strategies:
- The count of strong buy recommendations has seen a minimal decline, suggesting cautious optimism.
- There is a stable pattern in buy recommendations, hovering around 9-10 monthly.
- Hold ratings have decreased from a peak of 15 in late 2024 to 4 by mid-2025.
- Strong sell recommendations have remained largely negligible.
Percentage Trends
The percentage distribution of analyst ratings for Cardinal Health shows remarkable trends that surface certain shifts in sentiment:
- Strong buy ratings decreased, once peaking at 10% in mid-2024, now resting at around 5%.
- Buy ratings have maintained a steady 50% representation with minimal fluctuations.
- Hold ratings have dramatically dropped from a dominant 75% to a mere 20%.
- The cautiousness seen earlier in strong sell ratings remains unchanged.
- Overall, the sentiment portrays a transition from skepticism to a more balanced view of moderate optimism.
Latest Analyst Recommendations
The most recent analyst recommendations reflect a strong inclination towards maintaining current positions, suggesting consistent confidence in the company's valuation:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-16 | Overweight | Overweight | Morgan Stanley |
| 2025-06-13 | Overweight | Overweight | Morgan Stanley |
| 2025-06-13 | Neutral | Neutral | Citigroup |
| 2025-06-12 | Outperform | Outperform | Evercore ISI Group |
| 2025-06-10 | Buy | Buy | B of A Securities |
Analyst Recommendations with Change of Opinion
We observe movement in analyst sentiment, particularly upgrades hinting towards an uptick in market confidence. The following table highlights recent changes:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-03 | Overweight | Equal Weight | Wells Fargo |
| 2025-02-05 | Buy | Hold | Jefferies |
| 2025-01-08 | Buy | Hold | TD Cowen |
| 2025-01-07 | Outperform | In Line | Evercore ISI Group |
| 2025-01-06 | Buy | Neutral | B of A Securities |
Interpretation
The overall market estimation for Cardinal Health is leaning towards stability with a relatively positive bias in the eyes of analysts. The reluctance to issue strong buys indicates cautious optimism, while minimal strong sells point towards underlying confidence in fundamentals. Upgrades in recent months suggest an increase in investor trust. However, the stability of hold recommendations brings forth a balanced view, suggesting careful market navigation by analysts in light of macroeconomic uncertainties.
Conclusion
Cardinal Health displays a balanced yet cautiously optimistic market standing, underscored by consistent analyst recommendations favoring moderate buying and maintaining current positions. While the sector's inherent complexities and geopolitical challenges pose risks, the company's diverse operations offer resilience. The sentiment portends solid fundamentals and potential growth with a decisive commitment to reaffirm trust in the company's forward trajectory. As market conditions evolve, Cardinal Health’s strategic adaptability and performance metrics will be pivotal in maintaining analyst confidence.